Proto Axiom
Sydney, New South Wales, AustraliaFounded 20216+ employeesPrivate
$29.7M raisedSeries B+· last: series b (Aug 2024)· 2 rounds
Backed by(4 investors)
Australia produces world leading intellectual property in drug development and medical equipment, yet captures virtually none of the downstream commercialisation and job multipliers. This is in part due to underdeveloped domestic preclinical expertise. Proto Axiom on shores this capacity, keeping Australian IP in Australia.
